PRIME Dry Spell Over As EMA Says Yes To Pfizer & BioCryst
Executive Summary
This year’s first designations under the European Medicines Agency’s priority medicines scheme have gone to a maternal vaccine for an infection in newborns and a treatment for an ultra-rare bone disorder.
You may also be interested in...
Pink Sheet’s Top Seven Infographics Of 2022
From US drug pricing to Japan’s Sakigake expedited pathway, important regulatory developments and trends are easier to understand and track with Pink Sheet graphics.
MinervaX Hopes To Match Pfizer In Group B Streptococcus Vaccines Race
The Danish biotech has secured more funding for a late-stage program to advance its vaccine against Group B streptococcus, which is in a race for approval with Pfizer's product.
Gene Therapy For Lethal Glycogen Storage Disease Wins EMA PRIME Designation
Investigational products from Ultragenyx and MinervaX secured a place on the European Medicines Agency’s priority medicines scheme this month.